Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Advanced Therapy Medicinal Products CDMO Market, by Indication
1.4.2 North America Advanced Therapy Medicinal Products CDMO Market, by Product
1.4.3 North America Advanced Therapy Medicinal Products CDMO Market, by Phase
1.4.4 North America Advanced Therapy Medicinal Products CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2019, Jan – 2022, Aug) Leading Players
Chapter 4. North America Advanced Therapy Medicinal Products CDMO Market by Indication
4.1 North America Oncology Market by Country
4.2 North America Cardiology Market by Country
4.3 North America Central Nervous System & Musculoskeletal Market by Country
4.4 North America Infectious Disease Market by Country
4.5 North America Dermatology Market by Country
4.6 North America Endocrine, Metabolic, Genetic Market by Country
4.7 North America Immunology & Inflammation Market by Country
4.8 North America Ophthalmology Market by Country
4.9 North America Hematology Market by Country
4.1 North America Gastroenterology Market by Country
4.11 North America Others Market by Country
Chapter 5. North America Advanced Therapy Medicinal Products CDMO Market by Product
5.1 North America Gene Therapy Market by Country
5.2 North America Cell Therapy Market by Country
5.3 North America Tissue Engineered & Others Market by Country
Chapter 6. North America Advanced Therapy Medicinal Products CDMO Market by Phase
6.1 North America Phase I Market by Country
6.2 North America Phase II Market by Country
6.3 North America Phase III Market by Country
6.4 North America Phase IV Market by Country
Chapter 7. North America Advanced Therapy Medicinal Products CDMO Market by Country
7.1 US Advanced Therapy Medicinal Products CDMO Market
7.1.1 US Advanced Therapy Medicinal Products CDMO Market by Indication
7.1.2 US Advanced Therapy Medicinal Products CDMO Market by Product
7.1.3 US Advanced Therapy Medicinal Products CDMO Market by Phase
7.2 Canada Advanced Therapy Medicinal Products CDMO Market
7.2.1 Canada Advanced Therapy Medicinal Products CDMO Market by Indication
7.2.2 Canada Advanced Therapy Medicinal Products CDMO Market by Product
7.2.3 Canada Advanced Therapy Medicinal Products CDMO Market by Phase
7.3 Mexico Advanced Therapy Medicinal Products CDMO Market
7.3.1 Mexico Advanced Therapy Medicinal Products CDMO Market by Indication
7.3.2 Mexico Advanced Therapy Medicinal Products CDMO Market by Product
7.3.3 Mexico Advanced Therapy Medicinal Products CDMO Market by Phase
7.4 Rest of North America Advanced Therapy Medicinal Products CDMO Market
7.4.1 Rest of North America Advanced Therapy Medicinal Products CDMO Market by Indication
7.4.2 Rest of North America Advanced Therapy Medicinal Products CDMO Market by Product
7.4.3 Rest of North America Advanced Therapy Medicinal Products CDMO Market by Phase
Chapter 8. Company Profiles
8.1 Thermo Fisher Scientific, Inc. (Patheon, Inc.)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 SWOT Analysis
8.2 AGC Biologics, Inc. (AGC, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.2.5.3 Geographical Expansions:
8.3 Catalent, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.4 Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental Analysis
8.5.4 Recent strategies and developments:
8.5.4.1 Product Launches and Product Expansions:
8.5.4.2 Acquisition and Mergers:
8.5.4.3 Partnerships, Collaborations, and Agreements:
8.6 Lonza Group AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Geographical Expansions:
8.7 Celonic AG (JRS PHARMA GmbH & Co. KG)
8.7.1 Company Overview
8.8 Bio Elpida (Polyplus-transfection SA.)
8.8.1 Company Overview
8.9 Rentschler Biopharma SE
8.9.1 Company Overview
8.9.2 Recent strategies and developments:
8.9.2.1 Partnerships, Collaborations, and Agreements:
8.9.2.2 Acquisition and Mergers:
Unique Offerings 
